Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency: early-phase trial registry
3 of 5 indexed Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency: 5 US clinical trials tracked, 3 recruiting.
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Inozyme Pharma, running 5 of these trials.
Enrollment posture brief
Registry condition ectonucleotide-pyrophosphatasephosphodiesterase1-deficiency
OPEN 3 | RECR 60% | LATE 1 | EARLY 3 | RANK #3391 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency research.
Inozyme Pharma accounts for 5 of 5 trials (100%). 1 distinct sponsors appear on at least one study for this condition label.
-
Most Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials plan to enrol fewer than 100 people.
Median target enrolment is 27 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
Inozyme Pharma
NCT06302439
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Inozyme Pharma
NCT06462547
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
Inozyme Pharma
NCT05734196
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Inozyme Pharma
NCT06046820
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
Inozyme Pharma
NCT04686175
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Inozyme Pharma sponsors the most Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials on record, review their full trial history before evaluating a specific study. See Inozyme Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency condition card totals 5 registered trials; most-linked intervention INZ-701; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.